The FDA announced on March 31st that polidocanol (marketed in the US as Asclera) has been approved as a treatment for varicose veins. Asclera works its magic by damaging the cell lining in the blood vessels, causing them to close. Eventually the blood vessel is replaced by other types of tissue. The product is approved for veins less than 1 mm in diameter and reticular veins 1-3mm in diameter. (As a reference, there are 24 mm to one inch).There are three primary types of venous problems: varicose veins, reticular veins and spider veins. Spider veins are generally very tiny, while varicose veins are quite noticeable and generally develop on the legs. Reticular veins are mild and generally cause little in the way of discomfort. Vein treatments generally include lasers, broad band light and/or sclerosing agents.
Few side effects were noted by the FDA, including leakage or blood collection from the injected vessels at the injection site, as well as potential for bruising, irritation, discoloration and discomfort at the injection site.